SCHEMBL17341027

SCHEMBL17341027

C[C@]12CCC3[C@@H](CC[C@@H]4CCCC[C@]34C)C1CCC2=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 7/20 1.00
HSD17B3 P37058 5/20 0.69
AKR1B10 O60218 2/20 0.68
AKR1B1 P15121 2/20 0.68
OR51E2 Q9H255 1/20 0.68
GPBAR1 Q8TDU6 4/20 0.65
LMNA P02545 3/20 0.65
CYP3A4 P08684 3/20 0.65
MEN1 O00255 3/20 0.65
KMT2A Q03164 3/20 0.65
SHBG P04278 2/20 0.65
SERPINA6 P08185 2/20 0.65
MAPK1 P28482 1/20 0.65
PMP22 Q01453 1/20 0.65
G6PD P11413 1/20 0.65
CYP2D6 P10635 1/20 0.65
TSHR P16473 1/20 0.65
NFKB1 P19838 1/20 0.65
CYP2C19 P33261 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5925374 1.00 CYP19A1 (1.00) CYP19A1HSD17B3AKR1B10AKR1B1OR51E2
SCHEMBL12825203 1.00 CYP19A1 (1.00) CYP19A1HSD17B3AKR1B10AKR1B1OR51E2
SCHEMBL1552239 1.00 CYP19A1 (1.00) CYP19A1HSD17B3AKR1B10AKR1B1OR51E2
SCHEMBL1650324 1.00 CYP19A1 (1.00) CYP19A1HSD17B3AKR1B10AKR1B1OR51E2
SCHEMBL17817126 1.00 CYP19A1 (1.00) CYP19A1HSD17B3AKR1B10AKR1B1OR51E2
SCHEMBL1908291 1.00 CYP19A1 (1.00) CYP19A1HSD17B3AKR1B10AKR1B1OR51E2
SCHEMBL10273218 1.00 CYP19A1 (1.00) CYP19A1HSD17B3AKR1B10AKR1B1OR51E2
SCHEMBL12370187 1.00 CYP19A1 (1.00) CYP19A1HSD17B3AKR1B10AKR1B1OR51E2
SCHEMBL20714758 1.00 CYP19A1 (1.00) CYP19A1HSD17B3AKR1B10AKR1B1OR51E2
SCHEMBL12178030 1.00 CYP19A1 (1.00) CYP19A1HSD17B3AKR1B10AKR1B1OR51E2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251391-A9 NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-09-01 US disclosed
US-20150361125-A1 NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS UNIV WASHINGTON (US) 2015-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361125-A1 NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS GABRA4, GABRA5, GABRA3 CYP19A1 300/4885HSD17B3 139/4885AKR1B10 656/4885
US-20160251391-A9 NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS GABRA4, GABRA5, GABRA3 CYP19A1 300/4885HSD17B3 139/4885AKR1B10 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.